Schonfeld Strategic Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Schonfeld Strategic Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.17M	Sell	73,468 -109,151	-60%	-$6.32M	0.04%	430
2025 Q4	$7.53M	Buy	182,619 +54,366	+42%	+$2.11M	0.03%	430
2025 Q3	$5.05M	Sell	128,253 -43,786	-25%	-$1.12M	0.03%	587
2025 Q2	$3.21M	Buy	+172,039	New	+$3.23M	0.02%	750
2018 Q3	–	Sell	-625	Closed	-$135K	–	843
2018 Q2	$135K	Buy	+625	New	+$141K	0.01%	718

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Schonfeld Strategic Advisors's DNTH Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its Dianthus Therapeutics (DNTH) stake by 60% in Q1 2026, selling an estimated $6.32M and leaving 73,468 shares worth $6.17M. The position accounts for 0.04% of the portfolio, ranked #430.

Schonfeld Strategic Advisors first reported a position in DNTH in Q2 2018 and has held it in 5 quarters since. The position peaked at $7.53M in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

Schonfeld Strategic Advisors held 73,468 shares of Dianthus Therapeutics worth $6.17M as of Q1 2026.
Schonfeld Strategic Advisors sold 109,151 Dianthus Therapeutics shares in Q1 2026, an estimated $6.32M.
Dianthus Therapeutics made up 0.04% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #430 holding.
Schonfeld Strategic Advisors first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 5 quarters since.
Schonfeld Strategic Advisors's Dianthus Therapeutics position peaked at $7.53M in Q4 2025.
241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.